Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the ...

Novo Nordisk reported better-than-expected third-quarter sales for its weight-loss drug Wegovy, calming investor concerns ...

Novo Nordisk's sales of Wegovy surpassed expectations, calming investor concerns about competition from Eli Lilly. Shares ...

Novo Nordisk (NVO) posts Q3 sales for its weight loss drug Wegovy, contrasting rival Eli Lilly's (LLY) quarterly miss for its obesity drug, Zepbound. Read more here.

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

Some patients are using lower-than-recommended dosages of generic weight-loss drugs to slim down ... Last week, the Food and ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Americans are still eagerly seeking prescriptions for Eli Lilly and Novo Nordisk's weight-loss and diabetes drugs but cannot ...

Novo Nordisk reports earnings Wednesday morning, with sales of blockbuster weight-loss drugs Ozempic and Wegovy expected to continue driving the Danish drugmaker's results higher.

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

AstraZeneca (AZN) said Monday at the ObesityWeek conference in San Antonio, Texas that its experimental obesity pill was well-tolerated by ...